Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BH7Z
|
|||
| Former ID |
DNCL002791
|
|||
| Drug Name |
Girentuximab I-124
|
|||
| Synonyms |
Redectane (TN)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 2 | [1] | |
| Company |
Wilex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase IX (CA-IX) | Target Info | Enhancer | [2], [3] |
| KEGG Pathway | Nitrogen metabolism | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Reversible Hydration of Carbon Dioxide | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407. | |||
| REF 3 | Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. J Nucl Med. 2014 Jun;55(6):1035-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.